- Home
- BRY vs SGMT Comparison
BRY vs SGMT Comparison
Compare BRY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- SGMT
- Stock Information
- Founded
- BRY 1909
- SGMT 2006
- Country
- BRY United States
- SGMT United States
- Employees
- BRY N/A
- SGMT N/A
- Industry
- BRY Oil & Gas Production
- SGMT
- Sector
- BRY Energy
- SGMT
- Exchange
- BRY Nasdaq
- SGMT Nasdaq
- Market Cap
- BRY 249.1M
- SGMT 238.7M
- IPO Year
- BRY N/A
- SGMT 2023
- Fundamental
- Price
- BRY $3.77
- SGMT $7.31
- Analyst Decision
- BRY Hold
- SGMT Strong Buy
- Analyst Count
- BRY 2
- SGMT 7
- Target Price
- BRY $4.00
- SGMT $26.57
- AVG Volume (30 Days)
- BRY 2.7M
- SGMT 480.3K
- Earning Date
- BRY 11-06-2025
- SGMT 11-12-2025
- Dividend Yield
- BRY 3.17%
- SGMT N/A
- EPS Growth
- BRY N/A
- SGMT N/A
- EPS
- BRY 0.07
- SGMT N/A
- Revenue
- BRY $701,914,000.00
- SGMT N/A
- Revenue This Year
- BRY N/A
- SGMT N/A
- Revenue Next Year
- BRY N/A
- SGMT N/A
- P/E Ratio
- BRY $58.02
- SGMT N/A
- Revenue Growth
- BRY N/A
- SGMT N/A
- 52 Week Low
- BRY $2.11
- SGMT $1.73
- 52 Week High
- BRY $5.90
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- BRY 54.72
- SGMT 52.06
- Support Level
- BRY $3.60
- SGMT $7.11
- Resistance Level
- BRY $3.89
- SGMT $7.66
- Average True Range (ATR)
- BRY 0.13
- SGMT 0.40
- MACD
- BRY -0.05
- SGMT 0.11
- Stochastic Oscillator
- BRY 30.77
- SGMT 76.45
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.